29Jul
National Retailer Pulls CBD Products From Shelves in Response to FDA Warning to Product Manufacturer
On Monday, July 22, the U.S. Food and Drug Administration (FDA) took a rare and significant step in issuing a warning letter to Curaleaf Holdings, Inc. (Curaleaf), one of the country’s larger producers of CBD-based products, regarding Curaleaf’s...
By:
Manatt, Phelps & Phillips, LLP
Related
A federal judge took a pause from his New Year’s Eve revelries to hand a big victory to California ...
Read More >
The World Health Organization declared the outbreak of the novel coronavirus disease (COVID-19) a pa...
Read More >
As COVID-19 continues to cause uncertainty in M&A transactions, investors should have a heightened i...
Read More >
The Kansas Supreme Court recently reversed the Kansas Court of Appeals, and re-instated a three-plus...
Read More >
The use of net asset value finance by private equity firms has spiked under COVID-19 as managers exp...
Read More >
At the heart of tax qualified retirement plan compliance is a requirement to timely adopt plans and ...
Read More >